Search clinical trials for: HMPL-453

Total 6961 results

Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hutchison Medipharma Limited

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Hutchison Medipharma Limited

Active, not recruiting

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP)

China
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Hutchison Medipharma Limited

Completed

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Tumors

United States, Italy
Hutchison Medipharma Limited

Terminated

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor (HMPL-309)

Cancer

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited
Nutrition Science Partners Limited

Terminated

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis (NATRUL-4)

Ulcerative Colitis

United States
Hutchison Medipharma Limited

Completed

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Biliary Tract Cancer

China
Hutchmed

Completed

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Intrahepatic Cholangiocarcinoma

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Metastatic Non-small Cell Lung Cancer

China
Hutchison Medipharma Limited

Completed

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Hutchison Medipharma Limited

Completed

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Crohn's Disease
Hutchmed

Not yet recruiting

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Hematological Malignancies
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
Hutchison Medipharma Limited

Completed

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

Ulcerative Colitis
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Hutchison Medipharma Limited

Recruiting

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin's Lymphoma

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Hutchison Medipharma Limited

Completed

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (CRC-C1721)

Relative Bioavailability

China
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
NYU Langone Health
National Cancer Institute (NCI)

Completed

Phenethyl Isothiocyanate in Preventing Lung Cancer in People Who Smoke

Lung Cancer
Hutchison Medipharma Limited

Recruiting

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

Non-small Cell Lung Cancer

China
Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
Hutchison Medipharma Limited

Active, not recruiting

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA)

Warm Antibody Autoimmune Hemolytic Anemia

China
Hutchison Medipharma Limited

Active, not recruiting

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

Metastatic Colorectal Cancer | Metastatic Colon Cancer

United States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
Hutchison Medipharma Limited

Completed

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Healthy Subject

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Chinese PLA General Hospital
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
Hutchison Medipharma Limited
Sun Yat-sen University

Active, not recruiting

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (FRUTIGA)

Advanced Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Liver Metastasis Colon Cancer | Advanced Colorectal Carcinoma

China
China Medical University, China

Not yet recruiting

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
Hutchmed

Not yet recruiting

A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia
N.M. Wulffraat

Completed

Treatment of Steroid Resistant GVHD by Infusion MSC (MSCforGVHD)

Graft-versus-host-disease

Netherlands
University of Wisconsin, Madison
National Institutes of Health (NIH); National Center for Complementary and...

Completed

Healthy Minds Program App Dosage

Depression | Anxiety | Psychological Distress

United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
BeiGene
Hutchison Medipharma Limited

Completed

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China
University of Maryland, Baltimore
University of Florida

Not yet recruiting

Resilient HIV Implementation Science With SGM Youths Using Evidence (RISE)

Hiv
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Unknown

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China

Search clinical trials for: HMPL-453

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations